ストックスクリーナーアプリを入手
0.9603
3.25%
0.0302
Oncolytics Biotech Inc (ONCY) 最新ニュース
Oncolytics Biotech (NASDAQ:ONCY) Upgraded to Hold at Wall Street Zen - MarketBeat
Oncolytics Biotech: Financial Data Forecasts Estimates and Expectations | ONYN | US68237V1035 - MarketScreener
Oncolytics Biotech’s U.S. Move Resets Regulatory Path And Valuation Debate - sahmcapital.com
Oncolytics Biotech: Target Price Consensus and Analysts Recommendations | ONCY | US68237V1035 - marketscreener.com
Oncolytics Biotech Inc.: Financial Data Forecasts Estimates and Expectations | ONCY | US68237V1035 - MarketScreener
Oncolytics Biotech: Revenue and Earnings Analysts Forecasts Revisions | ONCY | US68237V1035 - MarketScreener
Oncolytics Biotech Inc.: Fundamental Analysis and Financial Ratings | ONCY | US68237V1035 - MarketScreener
ONCY Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Oncolytics Biotech Inc. (ONCY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Oncolytics Biotech Completes Domicile Change to the United States - MarketScreener
Stocks in play: Oncolytics Biotech Inc - Barchart
Oncolytics Biotech® Completes Domicile Change to the United States - Sahm
Oncolytics completes reincorporation from Canada to Nevada By Investing.com - Investing.com South Africa
Oncolytics Biotech | 10-K: FY2025 Annual Report - Moomoo
Oncolytics Biotech’s Nevada Move Resets Capital Access And Dilution Trade Off - Yahoo Finance
Oncolytics Biotech Completes Domestication to Nevada with New Governance - TipRanks
Oncolytics (ONCY) Completes Move to US Incorporation - GuruFocus
Oncolytics Biotech (NASDAQ:ONCY) Releases Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Oncolytics Biotech Completes Move to U.S., Becomes Nevada Corporation and Sets San Diego as New Headquarters - Minichart
[8-K] ONCOLYTICS BIOTECH INC Reports Material Event - Stock Titan
Oncolytics shifts to Nevada as San Diego becomes new headquarters - Stock Titan
Oncolytics Biotech (ONCY) re-registers $139M; $250M shelf available - Stock Titan
ONCY SEC FilingsOncolytics Biotech Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Aug Outlook: Is Oncolytics Biotech Inc undervalued by DCF analysis2026 Price Swings & Real-Time Volume Analysis - baoquankhu1.vn
[POS AM] ONCOLYTICS BIOTECH INC SEC Filing - Stock Titan
Aug Setups: Can Oncolytics Biotech Inc expand its profit margins2026 Geopolitical Influence & AI Forecasted Stock Moves - baoquankhu1.vn
Oncolytics Biotech Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Oncolytics Biotech (NASDAQ: ONCY) flags going concern and funding risk - Stock Titan
Sentiment Recap: Will Oncolytics Biotech Inc outperform the market in YEAR2026 Snapshot & Verified Momentum Stock Watchlist - baoquankhu1.vn
ONCY Stock Price, Quote & Chart | ONCOLYTICS BIOTECH INC (NASDAQ:ONCY) - ChartMill
Is It Time To Reassess Oncolytics Biotech (ONCY) After Recent Trial Progress News? - Sahm
Aug Closing: Is Oncolytics Biotech Inc stock a good dividend stock2026 Setups & Free Long-Term Investment Growth Plans - baoquankhu1.vn
If You Invested $1,000 in Oncolytics Biotech Inc (ONCY) - Stock Titan
Oncolytics Biotech Inc. Adopts New Articles and Notice of Articles Following Continuance to British Columbia Corporate Law - Minichart
Oncolytics Biotech completes first step of redomestication to British Columbia - Investing.com UK
Oncolytics Biotech completes first step of redomestication to British Columbia By Investing.com - Investing.com India
Form 8K Oncolytics Biotech Inc. For: 20 March By Investing.com - Investing.com South Africa
Form 8K Oncolytics Biotech Inc. For: 20 March - Investing.com
Oncolytics Biotech Shifts Corporate Domicile to British Columbia - TipRanks
Oncolytics Biotech (NASDAQ: ONCY) outlines move from Canada to Nevada - stocktitan.net
Oncolytics Biotech to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026 - marketscreener.com
Oncolytics Biotech Shares Gain on Upcoming Clinical Data Presentations - AD HOC NEWS
Oncolytics Biotech® to Host Conference Call to Discuss Second Qu - GuruFocus
Oncolytics Biotech Showcases Pelareorep as Immune-Priming Backbone With New AACR 2026 Data - TipRanks
Oncolytics to present new data on Pelareorep at AACR 2026 - TipRanks
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology - marketscreener.com
Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care - The Globe and Mail
Oncolytics (ONCY) Presents Promising Cancer Research at AACR 202 - GuruFocus
Oncolytics Highlights New Pelareorep Data in Cancer Immunotherapy - TipRanks
Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026 - The Manila Times
Oncolytics Biotech (Nasdaq: ONCY) showcases new pelareorep immune-priming data at AACR 2026 - Stock Titan
Pancreatic cancer signal, breast tumor immune data put Oncolytics at AACR - stocktitan.net
Oncolytics Biotech Inc. (ONCY) Competitors - Meyka
Is It Time To Reconsider Oncolytics Biotech (ONCY) After A Huge DCF Valuation Gap? - simplywall.st
Growth Report: What is Oncolytics Biotech Incs market position2026 Growth vs Value & Fast Entry Momentum Alerts - baoquankhu1.vn
Insider Buying: James Parsons Acquires Additional Shares of Onco - GuruFocus
Insider Buying: Oncolytics Biotech (NASDAQ:ONCY) Director Purchases 10,000 Shares of Stock - MarketBeat
Oncolytics Biotech (ONCY) director adds 10,000 common shares - Stock Titan
Oncolytics Biotech (ONCY) CEO buys 5,050 common shares at $0.96 - Stock Titan
0.49%
1.47%
大文字化:
|
ボリューム (24 時間):